Tang et al. reported that treatment of prostate cancer cells (LNCaP) with 500 μg/ml BBI resulted in the inhibition of viability as measured in WST-1 assays, with the induction of Cx43 and expression of cleaved caspase-3 protein (41). Here, CASP3 is linked to prostate carcinoma.